Cover Image
市場調查報告書

aTyr Pharma, Inc.的產品平台分析

aTyr Pharma, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 321361
出版日期 內容資訊 英文 22 Pages
訂單完成後即時交付
價格
Back to Top
aTyr Pharma, Inc.的產品平台分析 aTyr Pharma, Inc. - Product Pipeline Review - 2015
出版日期: 2015年06月24日 內容資訊: 英文 22 Pages
簡介

aTyr Pharma, Inc.,是開發人類疾病的蛋白質治療藥的生物醫藥品企業。

本報告提供aTyr Pharma, Inc.的治療藥開發平台的現狀及各開發階段比較分析,各給藥途徑及各分子類型的治療藥評估,最新的開發平台趨勢相關資訊等。

aTyr Pharma, Inc.的基本資料

aTyr Pharma, Inc.概要

  • 主要資訊
  • 企業資料

aTyr Pharma, Inc.:R&D概要

  • 主要的治療範圍

aTyr Pharma, Inc.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

aTyr Pharma, Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 在前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

aTyr Pharma, Inc.:藥物簡介

  • ATYR-1940
  • Resokine
  • Tmax
  • 發炎性疾病、血液疾病、代謝性疾病、心血管疾病治療的蛋白質

aTyr Pharma, Inc.:開發平台分析

  • 各給藥途徑
  • 各分子類型

aTyr Pharma, Inc.:最近的開發平台趨勢

aTyr Pharma, Inc.:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07235CDB

Summary

Global Markets Direct's, 'aTyr Pharma, Inc. - Product Pipeline Review - 2015', provides an overview of the aTyr Pharma, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of aTyr Pharma, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of aTyr Pharma, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of aTyr Pharma, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the aTyr Pharma, Inc.'s pipeline products

Reasons to buy

  • Evaluate aTyr Pharma, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of aTyr Pharma, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the aTyr Pharma, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of aTyr Pharma, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of aTyr Pharma, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of aTyr Pharma, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • aTyr Pharma, Inc. Snapshot
    • aTyr Pharma, Inc. Overview
    • Key Information
    • Key Facts
  • aTyr Pharma, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • aTyr Pharma, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • aTyr Pharma, Inc. - Pipeline Products Glance
    • aTyr Pharma, Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • aTyr Pharma, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • aTyr Pharma, Inc. - Drug Profiles
    • ATYR-1940
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Resokine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Tmax
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Proteins for Inflammation, Hematological, Metabolic, Oncology, Neurodegenerative and Cardiovascular Disorder
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • aTyr Pharma, Inc. - Pipeline Analysis
    • aTyr Pharma, Inc. - Pipeline Products by Route of Administration
    • aTyr Pharma, Inc. - Pipeline Products by Molecule Type
  • aTyr Pharma, Inc. - Recent Pipeline Updates
  • aTyr Pharma, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • aTyr Pharma, Inc., Key Information
  • aTyr Pharma, Inc., Key Facts
  • aTyr Pharma, Inc. - Pipeline by Indication, 2015
  • aTyr Pharma, Inc. - Pipeline by Stage of Development, 2015
  • aTyr Pharma, Inc. - Monotherapy Products in Pipeline, 2015
  • aTyr Pharma, Inc. - Phase I, 2015
  • aTyr Pharma, Inc. - Preclinical, 2015
  • aTyr Pharma, Inc. - Discovery, 2015
  • aTyr Pharma, Inc. - Pipeline by Route of Administration, 2015
  • aTyr Pharma, Inc. - Pipeline by Molecule Type, 2015
  • aTyr Pharma, Inc. - Recent Pipeline Updates, 2015

List of Figures

  • aTyr Pharma, Inc. - Pipeline by Top 10 Indication, 2015
  • aTyr Pharma, Inc. - Pipeline by Stage of Development, 2015
  • aTyr Pharma, Inc. - Monotherapy Products in Pipeline, 2015
  • aTyr Pharma, Inc. - Pipeline by Top 10 Molecule Type, 2015
Back to Top